Asset | Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Orphan Diseases | ||||||
TPN-101 | Progressive Supranuclear Palsy (PSP) | In planning | ||||
TPN-101 | Amyotrophic Lateral Sclerosis (ALS) / Frontotemporal Dementia (FTD) | In planning | ||||
TPN-101 | Aicardi-Goutières Syndrome (AGS) | Ongoing | ||||
New Indications | ||||||
TPN-101 | Alzheimer's Disease & Others | In planning | ||||
Novel NRTIs | To be determined | |||||
Novel PKRi | Disorders of cognition |
AFTD Website FTD Registry NEALS Website |
NEALS Video: Dr. Merit Cudkowicz National ALS Registry ClinicalTrials.gov |
Dennis Podlesak CEO and Chair |
Eckard Weber, MD Chief Innovation Officer |
Michael Cordingley, PhD Chief Scientific Officer |
Andrew Satlin, MD Chief Medical Officer |
Lynne Rollins Chief Financial Officer |
Rick Orr Head, BD and Corp Counsel |
Walter Bee, PhD SVP Preclinical & Biomarker Development |
Mark Mugerditchian VP Manufacturing |
Priya Jambhekar Head, Regulatory |
Jay Soto Head, Clinical Operations |
Ethan Geier, PhD Senior Director, Research and Development |
John Sedivy, PhD Chair
Brown University
Kathy Burns, MD PhD
DFCI, Harvard Med School
George Church, PhD
Harvard University
Josh Dubnau, PhD
SUNY at Stony Brook
Rusty Gage, PhD
Salk Institute
Molly Hammel, PhD
Cold Spring Harbor Lab
Murali Doraiswamy, MD Chair
Duke University
Adam Boxer, MD
UCSF
Yanick Crow, MD, PhD
Univ. Edinburgh (AGS)
Merit Cudkowicz, MD
MGH
John Ravits, MD
UCSD
Dennis Podlesak CEO and Chair |
Brent Ahrens Director |
Bill Harrington, MD Director |
Daniel Hetu, MD Director |
Keith Katkin Director |
John Pacifico Director |
BT Slingsby, MD Director |
Eckard Weber, MD Director and Chief Innovation Officer |